Suppression of farnesyltransferase activity in acute myeloid leukemia and myelodysplastic syndrome: current understanding and recommended use of tipifarnib

Author： Epling-Burnette Pearlie K   Loughran Jr Thomas P  

Publisher： Informa Healthcare

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.19, Iss.5, 2010-05, pp. : 689-698

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Combining DNA methyltransferase and histone deacetylase inhibition to treat acute myeloid leukemia/myelodysplastic syndrome: Achievements and challenges

By Lübbert Michael   Kuendgen Andrea  

Cancer, Vol. 121, Iss. 4, 2015-02 ,pp. : 498-501

Blackwell Publishing

Access to resources Recommend Favorite

Antineoplastics: Acute myeloid leukaemia and myelodysplastic syndrome: case report

By  

Reactions Weekly, Vol. 1, Iss. 1029, 2004-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Antineoplastics: myelodysplastic syndrome and acute myeloid leukaemia: 7 case reports

By  

Reactions Weekly, Vol. 1, Iss. 1259, 2009-01 ,pp. : 7-8

Adis International

Access to resources Recommend Favorite

Hydroxycarbamide: Myelodysplastic syndrome and acute myeloid leukaemia: case report

By  

Reactions Weekly, Vol. 1, Iss. 1408, 2012-01 ,pp. : 19-19

Adis International

Access to resources Recommend Favorite

Temozolomide: Myelodysplastic syndrome and acute myeloid leukaemia: case report

By  

Reactions Weekly, Vol. 1, Iss. 1291, 2010-01 ,pp. : 43-43

Adis International

Access to resources Recommend Favorite